Q3 2023 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2023-11-14 · accession 0001727492-23-000011
$217.8M
Reported value
13
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORP | $58.6M | 26.9% | 9,243,627 | Common | SOLE |
| 016259202 | — | ALIMERA SCIENCES INC | $52.2M | 24.0% | 16,835,154 | Common | SOLE |
| 45845P958 | — | INTERCEPT PHARMACEUTICALS INC | $22.2M | 10.2% | 1,200,000 | PUT | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $22.1M | 10.2% | 7,622,413 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $20.1M | 9.25% | 1,081,360 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $19.9M | 9.14% | 910,730 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $15.4M | 7.07% | 1,683,836 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $3.0M | 1.37% | 183,064 | Common | SOLE |
| 000899104 | ADMA | ADMA BIOLOGICS INC | $2.1M | 0.98% | 597,513 | Common | SOLE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $1.0M | 0.46% | 259,593 | Common | SOLE |
| 75629F109 | RAH | SOCIETAL CDMO INC | $794,191 | 0.36% | 1,689,768 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $127,099 | 0.06% | 23,321 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $119,617 | 0.05% | 4,833 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.